252 related articles for article (PubMed ID: 30560271)
1. [Current insights into the role of HIF-PHD axis in renal anemia].
Cao JY; Liu BC
Sheng Li Xue Bao; 2018 Dec; 70(6):623-629. PubMed ID: 30560271
[TBL] [Abstract][Full Text] [Related]
2. Stabilizing HIF to Ameliorate Anemia.
Voit RA; Sankaran VG
Cell; 2020 Jan; 180(1):6. PubMed ID: 31951520
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
Koivunen P; Serpi R; Dimova EY
Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
5. HIF-PHD inhibitor regulates the function of group2 innate lymphoid cells and polarization of M2 macrophages.
Nagashima R; Ishikawa H; Kuno Y; Kohda C; Iyoda M
Sci Rep; 2023 Feb; 13(1):1867. PubMed ID: 36725898
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
7. Hematological, hepatic, and retinal phenotypes in mice deficient for prolyl hydroxylase domain proteins in the liver.
Duan LJ; Takeda K; Fong GH
Am J Pathol; 2014 Apr; 184(4):1240-1250. PubMed ID: 24508125
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic approach targeting the HIF-HRE system in the kidney.
Nangaku M
Adv Exp Med Biol; 2009; 645():81-6. PubMed ID: 19227454
[TBL] [Abstract][Full Text] [Related]
9. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
10. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
Yousaf F; Spinowitz B
Curr Hypertens Rep; 2016 Mar; 18(3):23. PubMed ID: 26894597
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
Kim SY; Yang EG
Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
[TBL] [Abstract][Full Text] [Related]
13. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Sugahara M; Tanaka T; Nangaku M
Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hasegawa S; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor prolyl-hydroxylase: purification and assays of PHD2.
Hewitson KS; Schofield CJ; Ratcliffe PJ
Methods Enzymol; 2007; 435():25-42. PubMed ID: 17998047
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression.
Stockmann C; Fandrey J
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):968-79. PubMed ID: 17002676
[TBL] [Abstract][Full Text] [Related]
17. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
Tanaka T; Eckardt KU
Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
[TBL] [Abstract][Full Text] [Related]
18. The role of HIF in cobalt-induced ischemic tolerance.
Jones SM; Novak AE; Elliott JP
Neuroscience; 2013 Nov; 252():420-30. PubMed ID: 23916558
[TBL] [Abstract][Full Text] [Related]
19. Andrographolide inhibits hypoxia-induced HIF-1α-driven endothelin 1 secretion by activating Nrf2/HO-1 and promoting the expression of prolyl hydroxylases 2/3 in human endothelial cells.
Lin HC; Su SL; Lu CY; Lin AH; Lin WC; Liu CS; Yang YC; Wang HM; Lii CK; Chen HW
Environ Toxicol; 2017 Mar; 32(3):918-930. PubMed ID: 27297870
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia Pathway Proteins are Master Regulators of Erythropoiesis.
Watts D; Gaete D; Rodriguez D; Hoogewijs D; Rauner M; Sormendi S; Wielockx B
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
